Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib + Azacitidine in Higher Risk Chronic Myeloid Neoplasia
NCT03326310Phase 1Recruiting
- Sponsor
- University of Chicago
- Start
- Sep 2018
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selumetinib in myelodysplastic syndrome (MDS), myelodysplastic/myeloproliferative neoplasm (MDS/MPN) and myelofibrosis (MF), sponsored by University of Chicago. Primary endpoint: Number of patients with adverse events up to 24 months. Started Sep 2018; status: recruiting.
02
Drugs
selumetinib
03
Conditions
myelodysplastic syndrome (MDS)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)myelofibrosis (MF)
Beyond the preview
Go deeper on NCT03326310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03326310.